본문 바로가기
KERD
논문KCI 등재

Efficacy of Oral Etidronate for Skeletal Disease in Japan

Tsuyoshi Takeda|Yoshihiro Sato|Jun Iwamoto
연세대학교의과대학 (Yonsei University College of Medicine)|2005.06|Yonsei Medical Journal|제46권 제3호|pp. 313-320

1

조회

0

다운로드

0

인용

0

참고문헌

주제분류의학일반

초록

Abstract

Etidronate is an oral bisphosphonate compound that is known to reduce bone resorption through the inhibition of osteoclastic activity. The efficacy of etidronate for involutional (postmenopausal and senile) and glucocorticoid-induced osteoporosis, as well as that for other skeletal diseases, was reviewed in Japanese patients. Cyclical etidronate treatment (200 mg or 400mg/day for 2 weeks about every 3 months) increases the lumbar bone mineral density (BMD) in patients with involutional osteoporosis and prevents incident vertebral fractures in patients with glucocorticoid-induced osteoporosis. The losses of the lumbar BMD in patients with liver cirrhosis and the metacarpal BMD in hemiplegic patients after stroke are prevented, and the lumbar BMD is possibly increased, preventing fragile fractures in adult patients with osteogenesis imperfecta type I. Furthermore, proximal bone resorption around the femoral stem is reduced and some complications may be prevented in patients who undergo cementless total hip arthroplasty. Oral etidronate treatment may also help to transiently relieve metastatic cancer bone pain followed by a decrease in abnormally raised bone resorption in patients with painful bone metastases from primary cancer sites, such as the lung, breast and prostate. Thus, oral etidronate treatment is suggested to be efficacious for osteoporosis, as well as other skeletal diseases associated with increased bone resorption, in Japanese patients. Randomized controlled trials needed to be conducted on a large number of patients to confirm these effects.

참고문헌 (32)

  1. "Etidronate for treating and preventing postmenopausal osteoporosis", pp.CD003376.~ (2001)
  2. "Summary of meta-analyses of therapies for postmenopausal osteoporosis", 23, pp.570~8 (2002)
  3. "Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis", 337, pp.382~7 (1997)
  4. "The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis", 17, pp.1512~26 (2002)
  5. "Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck", 65, pp.198~202 (1999)
  6. "Double-blind multicenter comparative study with alfacalcidol of etidronate disodium", pp.261~302
  7. "Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis", pp.370~6
  8. "Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis", 15(ne), pp.515~21 (2000)
  9. "Effect of intermittent cyclical treatment with etidronate disodium and calcium plus alphacalcidol in postmenopausal osteoporosis", 6, pp.133~6 (2001)
  10. "Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density and back pain in postmenopausal women with osteoporosis", 8, pp.532~7 (2003)
  11. "Combined treatment with vitamin K2 and bisphosphonate in postmenopausal women with osteoporosis", 44, pp.751~6 (2003)
  12. "Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis", 30, pp.474~9 (2003)
  13. "Steroid-induced osteoporosis", 31, pp.48~53 (2002)
  14. "Prevention of vertebral fractures with therapeutic agents in corticosteroid-induced osteoporosis", 10, pp.244~7 (2002)
  15. "Effects of menatetrenone on prevention of vertebral fracture in corticosteroid-induced osteoporosis", 16, pp.531~ (2001)
  16. "Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease", 30, pp.2673~9 (2003)
  17. "Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high-dose glucocorticoid and once- cycle etidronate therapy", 66, pp.196~9 (2000)
  18. "Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases", 31, pp.163~6 (2004)
  19. "Beneficial effect of intermittent cyclical etidtronate therapy in hemiplegic patients following an acute stroke", 15, pp.2487~94 (2000)
  20. "Prevention of secondary osteoporosis postmenopause in hemiplegia", 80(s), pp.169~74 (2001)
  21. "Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women", 81, pp.452~7 (2002)
  22. "Longitudinal changes of bone mineral content with age in patients with cirrhosis of the liver", 33, pp.236~40 (1998)
  23. "Effects of 1 2D3 on turnover and strength of bone in growing rats with liver cirrhosis induced by administration of carbon tetrachloride", 32, pp.275~83 (2003)
  24. "Cyclical etidronate for treatment of osteopenia in patients with cirrhosis of the liver", 22, pp.102~6 (2002)
  25. "Static and dynamic bone histomorphometry in children with osteogenesis imperfecta", 26, pp.581~9 (2000)
  26. "Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta", pp.993~7
  27. "Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density and back pain in postmenopausal women with osteoporosis", 8, pp.532~7 (2003)
  28. "Cyclical therapy with etidronate has a therapeutic effect against local osteoporosis after cementless total hip arthroplasty", 33, pp.144~9 (2003)
  29. "Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopania associated with type 2 Diabetes", 85, pp.2793~6 (2000)
  30. "Mechanisms of bone destruction in the development of skeletal metastasis", pp.507~8
  31. "Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer", 5, pp.54~7 (1995)
  32. "Monitoring alendronate therapy for osteoporosis", 14, pp.602~8 (1999)

관련 논문AI추천

Comparison of the Effects of Alendronate and Alfacalcidol on Hip Bone Mineral Density and Bone Turnover in Japanese Men Having Osteoporosis or Osteopenia with Clinical Risk Factors for FracturesHideo Matsumoto, Jun Iwamoto, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Yoshihiro Sato연세대학교의과대학 · Yonsei Medical Journal2009 · 제50권 제4호The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis박수연, 변지혜, 윤병호, 윤현구, 이수민, 장선미, 하용찬대한골대사학회 · 대한골대사학회지2017 · 제24권 제1호Denosumab, an effective osteoporosis treatment option for menSung Hye Kong대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제5호Intravenous Zoledronate for a Patient with Paget’s Disease김기철대한골대사학회 · 대한골대사학회지2014 · 제21권 제3호Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with DenosumabJung-Wee Park대한골대사학회 · 대한골대사학회지2021 · 제28권 제4호골다공증의 치료정윤석대한내과학회 · 대한내과학회지2010 · 제79권 제3호

이 간행물의 다른 논문 (14건)

Interest group influence over drug pricing policy reform in South Korea김한중, 정우진pp. 321-330Development of a Structural Model Explaining Medication Compliance of Persons with Schizophrenia민성길, 서미아pp. 331-340Limited Effect of CpG ODN in Preventing Type 1 Diabetes in NOD Mice조현철, 정춘희, 김미진, 심명숙, 신영구, 이병준, 박은섭, 김문규, 김수기pp. 341-346Effectiveness of Real-time Quantitative PCR Compare to Repeat (REP-)PCR for the Diagnosis of Charcot-Marie-Tooth Type 1A and Hereditary Neuropathy with Liability to Pressure Palsies최종락, 임종백, 선우일남, 이은경, 이창훈, 이운형pp. 347-352The Ocular Motility Disturbances in the Orbital Wall Fracture Patients유혜린, 윤영수, 이상훈pp. 359-367
원문 보기